Genetic advances uncover mechanisms of chemotherapy‐induced peripheral neuropathy

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting toxicity experienced in 30–40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN significantly affects...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2017-04, Vol.101 (4), p.450-452
Main Authors: Chua, KC, Kroetz, DL
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - adverse effects
Drug Discovery
Genome-Wide Association Study
Humans
Peripheral Nervous System Diseases - chemically induced
Peripheral Nervous System Diseases - genetics
Peripheral Nervous System Diseases - physiopathology
Quality of Life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting toxicity experienced in 30–40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN significantly affects a patient's quality of life. Recent genetic association studies are enhancing our understanding of CIPN pathophysiology and serve as a foundation for identification of genetic biomarkers to predict toxicity risk and for the development of novel strategies for prevention and treatment.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.590